Henao-Mejia et al. demonstrated that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression [16]. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.